Search results
ASCO24: Tagrisso in the spotlight, Caribou’s adjustment and Lilly’s KRAS competitor
BioPharma Dive via Yahoo Finance· 4 days agoAstraZeneca’s therapy could see wider use after ASCO data. Elsewhere, Caribou sought to explain an...
3 No-Brainer Stocks to Buy in June | The Motley Fool
The Motley Fool· 5 days agoYou're probably familiar with the old adage, "April showers bring May flowers." Here's why they picked AbbVie (ABBV 3.15%), AstraZeneca (AZN 1.63%), and...
3 No-Brainer Stocks to Buy in June
Motley Fool via Yahoo Finance· 5 days agoBut what does June bring? Three Motley Fool contributors think the new month should usher in great investing opportunities. Here's why they picked AbbVie...
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 7 days agolongest-serving chief executive, Pascal Soriot, has no plans to step down for now as the company...
ASCO 2024: What's New in Breast Cancer Research?
Medscape· 1 day agoDrs Alexandra Thomas and Virginia Kaklamani discuss highlights in breast cancer research from the ASCO 2024 Annual Meeting.
With new Enhertu data, an ADC could overtake chemo in breast cancer
BioPharma Dive via Yahoo Finance· 5 days agoStudy participants had already received one hormone therapy and a type of drug called a CDK 4/6...
Antibody-Drug Conjugate Picks Up Another Win in HR+/HER2-low Breast Cancer
MedPage Today· 5 days agoThe antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) significantly improved...
AstraZeneca’s breast cancer trial shows ‘unprecedented’ results | Honolulu Star-Advertiser
Honolulu Star-Advertiser· 5 days agoAstraZeneca and Daiichi Sankyo’s Enhertu slows the progression of breast cancer by about five months...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 2 days agoThe Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding (MoU) with AstraZeneca during BIO International ...
Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support...
Morningstar· 6 days agoTempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm ...